IP Library › Granted Patent US 10,624,931
Granted Patent B2
US 10,624,931 · App. 15/274,100 · Granted Apr 21, 2020

Umbilical tissue compositions and methods of use

Inventors: Alla Danilkovitch (Columbia, MD); Yi Duan-Arnold (Ellicott City, MD); Matthew Moorman (Chestertown, MD); Anne Lerch (Annapolis, MD); Jin-Qiang Kuang (Glenelg, MD)
Assignee: Osiris Therapeutics, Inc.
A61K35/51A01N1/021A61K35/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,931
App. No.
15/274,100
Granted
Apr 21, 2020
Kind
B2
Abstract

Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.

Claims (14)

1. A composition comprising umbilical tissue that has been isolated from a mammal, wherein one or more engineered channels extend through at least a portion of the umbilical tissue.

2. The composition of claim 1 , wherein the umbilical tissue is cryopreserved.

3. The composition of claim 1 , wherein the umbilical tissue is previously cryopreserved.

4. The composition of claim 1 , wherein the composition is devoid of viable immunogenic cells.

5. The composition of claim 1 , wherein the composition is devoid of blood vessels.

6. The composition of claim 2 , wherein the umbilical tissue comprises viable cells native to the umbilical tissue.

7. The composition of claim 6 , wherein the viable cells comprise mesenchymal stem cells, fibroblasts, epithelial cells, or a combination thereof.

8. The composition of claim 2 , wherein the umbilical tissue comprises one or more growth factors native to the umbilical tissue.

9. The composition of claim 2 , wherein the umbilical tissue comprises one or more cytokines native to the umbilical tissue.

10. The composition of claim 1 , wherein the umbilical tissue has a Wharton's jelly layer side and an amniotic epithelial layer side, wherein the one or more engineered channels are present on the Wharton's jelly layer side and do not extend through the amnion side.

11. The composition of claim 1 , wherein the one or more engineered channels extend through the entire umbilical tissue.

12. The composition of claim 1 further comprising a cryopreservation solution.

13. A method of producing the composition of claim 1 , comprising forming engineered channels in the umbilical tissue.

14. A method of treating damaged tissue comprising administering to the site of the damaged tissue the composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: DANILKOVITCH, ALLA; DUAN-ARNOLD, YI; MOORMAN, MATTHEW; LERCH, ANNE; KUANG, JIN-QIANG
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 052037/0982 →
Continuity (2)
Provisional Application 62222446 · Sep 23, 2015
Related Publication 20170136071A1 · May 18, 2017